# Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

> **NCT00684255** · PHASE1 · TERMINATED · sponsor: **New York Medical College** · enrollment: 1 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Systemic Sclerosis

## Interventions

- **PROCEDURE:** Reduced Intensity Allogeneic Transplant
- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **DRUG:** Campath

## Key facts

- **NCT ID:** NCT00684255
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** inactive
- **Last updated:** 2014-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684255, "Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00684255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*